BB
AKCA

BB Biotech’s Akcea Therapeutics Inc AKCA Stock Holding History

BB Biotech’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$67.4M Sell
2,377,638
-8,833
-0.4% -$257K 1.69% 20
2018
Q4 		$71.9M Hold
2,386,471
– – 2.3% 16
2018
Q3 		$83.6M Sell
2,386,471
-97,600
-4% -$2.95M 2.21% 16
2018
Q2 		$58.9M Buy
2,484,071
+94,500
+4% +$2.26M 1.7% 17
2018
Q1 		$61.2M Buy
2,389,571
+1,140,921
+91% +$24.6M 1.69% 18
2017
Q4 		$21.7M Buy
+1,248,650
New +$24.5M 0.61% 25

Other funds holding AKCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SC
Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BB Biotech's AKCA Position: Q1 2019 in Review

BB Biotech reduced its Akcea Therapeutics Inc (AKCA) stake by 0.37% in Q1 2019, selling an estimated $257K and leaving 2,377,638 shares worth $67.4M. The position accounts for 1.69% of the portfolio, ranked #20.

BB Biotech first reported a position in AKCA in Q4 2017 and has held it in 6 quarters since. The position peaked at $83.6M in Q3 2018. 74 funds tracked by Wall St. Rank hold AKCA as of Q1 2019.

  • BB Biotech held 2,377,638 shares of Akcea Therapeutics Inc worth $67.4M as of Q1 2019.
  • BB Biotech sold 8,833 Akcea Therapeutics Inc shares in Q1 2019, an estimated $257K.
  • Akcea Therapeutics Inc made up 1.69% of BB Biotech's portfolio in Q1 2019, its #20 holding.
  • BB Biotech first reported a position in Akcea Therapeutics Inc in Q4 2017 and has held it in 6 quarters since.
  • BB Biotech's Akcea Therapeutics Inc position peaked at $83.6M in Q3 2018.
  • 74 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q1 2019.

Based on BB Biotech's 13F filing for Q1 2019, filed 13 May 2019.